A landscape analysis of clinical trials in cancer pain management: current trends and emerging therapeutic targets
Front Oncol. 2026 May 19;16:1795684. doi: 10.3389/fonc.2026.1795684. eCollection 2026.
ABSTRACT
BACKGROUND: Despite a growing volume of clinical research, cancer pain management remains dependent on opioid-centric paradigms with few therapeutic breakthroughs. To identify innovation gaps and guide future research, a systematic evaluation of the global clinical trial landscape is imperative.
METHODS: We conducted a comprehensive landscape analysis of 632 interventional cancer pain trials(1994-2025) from the Trialtrove database. Key characteristics including temporal trends, trial phases, therapeutic targets, and primary endpoints were extracted and analyzed.
RESULTS: Our analysis revealed a significant "innovation paradox." Although trial initiations have increased 3.2-fold since 2000, research remains focused on established mechanisms. Late-stage (Phase III, 38%) investigations predominated over scarce early-phase (Phase I, 13%) studies. Over half (52%) of all trials targeted opioid receptors, while emerging targets like NaV1.7 (18%)-a peripheral sodium channel implicated in inherited pain syndromes-and cannabinoid receptors (5%) were underrepresented. All percentages reflect proportions of the total 632 trials and categories may overlap. Furthermore, primary endpoints overwhelmingly favored unidimensional pain intensity scales (35.8%) over functional or quality-of-life (QoL) metrics. The most advanced innovations are currently limited to dual-mechanism agents (e.g., tapentadol combining MOR agonism and norepinephrine reuptake inhibition) and novel delivery systems (e.g., iontophoretic transdermal patches or intrathecal pumps).
CONCLUSION: The cancer pain research ecosystem exhibits substantial volume growth unmatched by mechanistic innovation. To surmount this therapeutic stagnation, future priorities must include expanding early-phase trials on novel pathways (e.g., tumor-microenvironment interactions), adopting composite endpoints integrating pain with function and QoL, and leveraging real-world evidence and AI-driven phenotyping to advance precision analgesia. This paradigm shift is critical to addressing the multidimensional burden of cancer pain.
PMID:42239899 | PMC:PMC13225961 | DOI:10.3389/fonc.2026.1795684